The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression

INTRODUCTION: Neoadjuvant trastuzumab plus chemotherapy may affect programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in HER2-positive breast cancer. Discordant results were shown on the correlation between PD-L1 expression or TILs and the effectiveness of neoadju...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Mao, Chi, Yajing, Zhang, Jianbo, Chang, Jin, Yang, Hui, Yin, Sha, Tan, Qiaorui, Man, Xiaochu, Li, Huihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766296/
https://www.ncbi.nlm.nih.gov/pubmed/35070953
http://dx.doi.org/10.3389/fonc.2021.706606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766296/
https://www.ncbi.nlm.nih.gov/pubmed/35070953
http://dx.doi.org/10.3389/fonc.2021.706606

Ejemplares similares